AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV, SC, IT
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO, NG, IV
Study NCT02828358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given PO, IV
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO, IV
Study NCT02828358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO, NG
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, PO
Study NCT02828358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO, NG
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO, NG
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03371212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual mobility cohort
Description: Patients will receive the Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell.
Study NCT01577108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: oral taking 2 capsules before sleeping per day for 14 days
Study NCT01577108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral taking 2 capsules before sleeping per day for 14 days
Study NCT04301037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension band wires
Description: medial malleolus fracture fixed with tension band wiring): 2 k.wires (1.6 mm) are inserted perpendicular to the fracture site. Again the position is checked under image intensification for the correct direction and length. We drilled a 2.5mm hole with a protection sleeve, 2-3cm above the level of the horizontal joint line, aiming the drill bit slightly inferiorly to avoid screw pullout. We inserted a 3.5mm unicortical screw about 30 mm in length (with or without washer), 2-3mm is left for the wire between the bone and screw head before full tightening. A steel wire is constructed into a figure of eight between the screw the reduction k. wires, then twisted to achieve interfragmentary compression
Study NCT04301037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cannulated screws
Description: In group 2 (15 patients with medial malleolus fixed by 2 cannulated screws): Two guide wires (1.6mm) are inserted perpendicular to the fracture site, the appropriate length, proper insertion site including the distance from the articular surface is checked fluoroscopically .the length is measured .drilling of the bone through the threaded guide wire with a cannulated drill bit (3.2mm). A two 4.5mm partially threaded cannulated screws (with or two washers) are inserted through the guide to achieve Compression, the guide wires are then removed
Study NCT03726411 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal therapy
Description: scaling and root planing
Study NCT05146895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod treatment
Description: As an control arm, for patients with flat warts
Study NCT05146895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local Hyperthermia at 44℃
Description: As an experimental arm, for patients with flat warts
Study NCT05510375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract
Description: 2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
Study NCT05510375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin
Study NCT05510375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract placebo
Description: Cocoa extract placebo
Study NCT05510375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa extract placebo
Description: Cocoa extract placebo
Study NCT05510375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo
Study NCT05510375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo
Study NCT01267045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
Study NCT02624752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: Comparison of enhanced oral nutrition supplementation versus standard of care
Study NCT02339584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension
Study NCT02339584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 10 mg/mL eye drops, suspension
Study NCT02339584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 2 mg/mL eye drops, solution
Study NCT02339584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Inactive ingredients used as a placebo for masking purposes
Study NCT02095093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intellijoint HIP
Description: Intellijoint HIP is an intra-operative, imageless intelligent instrument used to provide real-time information to surgeons about leg length and hip offset changes during total hip replacement surgery.
Study NCT02095093 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Outrigger
Description: The outrigger is a pin and caliper device that is used to assess leg length and offset during total hip arthroplasty. It is the current standard of care at Mount Sinai Hospital.
Study NCT01402011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25% dextrose in shoulder entheses
Description: injections of 1 mL of 25% dextrose and .1% lidocaine solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
Study NCT01402011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: .1% lidocaine in shoulder entheses
Description: injections of 1 mL of .1% lidocaine 'ssolution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
Study NCT01402011 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: .1% lidocaine subcu. above shouldr enth.
Description: injections of 1 mL of .1% lidocaine solution subcutaneously, above the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic, above the insertion of the teres minor and the triceps on the scapula.
Study NCT03371212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cohort
Description: Patients will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell
Study NCT04323046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03607487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 tablet administered orally once daily at the protocol-defined dose.
Study NCT03607487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet administered orally once daily.
Study NCT02836093 — intervention group
Intervention type: BEHAVIORAL
Intervention: FACIT-Fatigue 52-point questionnaire
Study NCT01684956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intradermal injection
Study NCT01684956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection
Study NCT00818480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: continuous infusion
Study NCT01980940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% DMSO Gel
Description: Etoricoxib 75 mg 4% DMSO gel applied topically.
Study NCT01980940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% PG Gel
Description: Etoricoxib 75 4% PG gel applied topically.
Study NCT01980940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 150 mg 4% DMSO Gel
Description: Etoricoxib 150 mg 4% DMSO gel applied topically.
Study NCT01980940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 150 mg 4% PG Gel
Description: Etoricoxib 150 mg 4% PG gel applied topically.
Study NCT01980940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 163 mg 4% DMSO gel
Description: Etoricoxib 163 mg 4% DMSO gel applied topically
Study NCT04323046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies, given in person or online
Study NCT04323046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies, given in person or online
Study NCT05594186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.
Description: Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.
Study NCT02035657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: Glucopyranosyl Lipid A in Stable Emulsion
Study NCT01395745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blisibimod
Description: blisibimod administered via subcutaneous injection every week for 52 weeks
Study NCT01395745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered weekly via subcutaneous injection for 52 weeks
Study NCT02085720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Description: As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
Study NCT02720458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized gradual hypnotic taper
Description: The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
Study NCT02720458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized gradual hypnotic taper
Description: The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
Study NCT02720458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short-term simple self-help program
Description: The short-term simple self-help program consists in:~* Restriction of time in bed~* Stimulus control instructions~The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program.
Study NCT01085214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01085214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
Study NCT00789555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.6% nasal spray (PATANASE)
Description: Two sprays in each nostril twice a day (morning and evening) for up to 12 months
Study NCT00789555 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine nasal spray vehicle, pH 3.7
Description: Two sprays in each nostril twice a day (morning and evening) for up to 12 months
Study NCT00789555 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine nasal spray vehicle, pH 7.0
Description: Two sprays in each nostril twice a day (morning and evening) for up to 12 months
Study NCT03226041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous monitor (TCM-4 monitor)
Description: TCM-4 monitor, which had changed new electrode membrane and was calibrated by the same person(who had been trained systematically) before each placement. The electrode should be heated to 44℃, then fixed it to the anterior part of chest in the location of lateral position after remove grease by alcohol. The positon of electrode must be changed every 2 hours in order to avoid thermal injury, and should be calibrated again.
Study NCT03612570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano-Pulse Stimulation Device
Description: NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.
Study NCT02972307 — intervention group
Intervention type: OTHER
Intervention: wheelchair skills
Description: the extent to which caregivers enhance the wheelchair skills of powered wheelchair users
Study NCT02145884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: timolol maleate 0.5% gel
Description: Apply timolol gel 1-2 drops twice a day to lesion
Study NCT02334657 — intervention group
Intervention type: OTHER
Intervention: SF-36
Description: postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)
Study NCT04821167 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic orchiopexy for intra-canalicular testis
Description: laparoscopic orchiolysis of abnormal fibrous attachments and then lap assisted transcrotal fixation of the testis in subdartos pouch for intra-canalicular testis
Study NCT00767026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE (Creating Opportunities for Parent Empowerment)
Description: Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.
Study NCT00767026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard education
Description: This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
Study NCT03717753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pathway
Description: The study team emphasizes that all components of the pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the pathway will receive these standard of care components. Both groups will receive identical postoperative follow-up.
Study NCT02247128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin + clopidogrel
Study NCT02247128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin monotherapy
Study NCT02247128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OAC + clopicogrel
Study NCT02247128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OAC monotherapy
Study NCT04163757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: crocin
Description: 2 tablets crocin per day
Study NCT04163757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tablets placebo per day
Study NCT04055012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500mg tabs of Metformin Extended Release
Study NCT01980940 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo gel applied topically.
Study NCT01980940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 50 mg 4% DMSO
Description: Etoricoxib 50 mg 4% DMSO gel applied topically.
Study NCT04055012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 500mg tabs of Metformin Extended Release
Study NCT04055012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tabs
Study NCT04055012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo Tabs
Study NCT03518151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product placement intervention
Description: The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section and island in the first aisle; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
Study NCT04483115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: Tablets; Oral; Single dose
Study NCT04483115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets; Oral; Single dose